TDE-HF-302 An Open-label Extension Study of Oral Treprostinil in Subjects with Pulmonary Hypertension (PH) Associated with Heart Failure with Preserved Ejection Fraction (HFpEF) - A Long-Term Follow-up to Study TDE-HF-301

Grants and Contracts Details

StatusFinished
Effective start/end date10/27/175/27/20

Funding

  • United Therapeutics Corporation: $18,288.00